PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Clozapine - Parkinson's Disease (psychosis)
PAD Profile : Clozapine - Parkinson's Disease (psychosis) Important
Keywords :
psychotic symptoms, PD, hallucinations, delusions, psychosis in Parkinson's disease
Brand Names Include :
Clozaril, Denzapine, Zaponex
Important Information :
Patient monitoring and registration required
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Information
03 September 2024
Committee Recommendations
Date
Committee Name
Narrative
14 September 2022
Surrey Heartlands Medicines Safety Committee (MSC)
Clozapine - IMPORTANT Information for primary care - can be found in the attachment below
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Clozapine may be used to treat hallucinations and delusions in Parkinson's Disease (unlicensed use) in patients with no cognitive impairment if quetiapine has not been effective.
Clozapine requires long-term monitoring of toxicity with the patient, prescriber and dispenser being registered with the clozapine monitoring service. As such, prescribing responsibility should remain with the Parkinson's specialist.
Associated BNF Codes
04. Central Nervous System
04.02.01. Antipsychotic drugs